The funnel versus the flat rate: the category’s loudest acquisition machine against its best-known single-number pitch.
The two models
Hims is the category’s marketing heavyweight with its most contested model: after its Novo Nordisk partnership collapsed in June 2025, it leaned into “personalized” compounded semaglutide — the legal rationale regulators and manufacturers dispute most directly. Advertised entry prices are aggressive; true maintenance-dose totals are exactly what our pending verification exists to establish.
Henry Meds advertises the market’s best-known flat-rate compounded pricing — a structure we favor on principle, because flat rates make teaser math impossible. Whether the advertised flat number survives contact with membership terms, shipping, and dose realities is precisely what its pending verification pass will establish; until then, no Henry figure is published here.
Verified vs pending — read this before the marketing
Neither provider on this page has completed price verification, so this comparison stays structural — business models, pricing architecture, and the questions each must answer — with zero advertised numbers repeated as facts. The only verified figures on this site today sit in the ledger.
Marketing spend versus price legibility
Every acquisition dollar in a funnel is recovered somewhere downstream — which is why teaser anatomy reads Hims-style entry offers so closely — while a flat rate stakes its whole pitch on one legible number. Legibility is a virtue only if the number survives checkout with membership, shipping, and dose reality attached; that survival test is precisely the pending verification for both, and this page repeats neither’s advertised figures in the meantime.
Go deeper
Full files: Hims · Henry Meds. Decision tools: the quiz routes by coverage and priorities; the calculator turns any quote into a true 12-month number; the ledger holds every verified figure and every pending slot.